Cancer

A member of the CRC program, St Vincent’s Institute and Bio21 Institute, University of Melbourne’s Professor Michael Parker and his team contributed to the structural biology of the target proteins KAT6A and KAT6B, as well as the corresponding selective inhibitors.

Bio21's Dr David De Souza and Professor Malcolm McConville working together with Dr Kate Sutherland and Dr Sarah Best from the Walter and Eliza Hall Institute, have confirmed the mutations responsible for lung adenocarcinomas and identified unique diagnostic signatures.

Research linking cancer drugs to overcoming drug-resistant malaria puts team in contention for Eureka Prize